Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-04 · accession 0001193125-26-096538 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-06 | 2026-03-04 | TEVA | Sabag Mark | See "Remarks" | M - OptEx | — | +52.1K | 252.7K | +26% | — |
| DM | 2026-03-06 | 2026-03-04 | TEVA | Sabag Mark | See "Remarks" | M - OptEx | $0.00 | -52.1K | 37.2K | -58% | $0 |
| D | 2026-03-06 | 2026-03-04 | TEVA | Sabag Mark | See "Remarks" | A - Grant | $0.00 | +30.4K | 30.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-03-04 | M | A | 18,601 | — | 271,319 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 2 | Common | Ordinary Shares | 2026-03-04 | M | A | 33,512 | — | 252,718 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 3 | Derivative | Restricted Share Units | 2026-03-04 | M | D | 33,512 | $0.00 | 0 | D | — · — to — | 33,512 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F3) Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. |
| 4 | Derivative | Restricted Share Units | 2026-03-04 | A | A | 30,385 | $0.00 | 30,385 | D | — · — to — | 30,385 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F5) Restricted share units were granted on March 4, 2026, with 7,596 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 7,597 vesting on March 4, 2030. |
| 5 | Derivative | Restricted Share Units | 2026-03-04 | M | D | 18,601 | $0.00 | 37,202 | D | — · — to — | 18,601 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F4) Restricted share units were granted on March 4, 2024, with 18,601 vested on each of March 4, 2025 and March 4, 2026, and 18,601 vesting on each of March 4, 2027 and March 4, 2028. |